Related Experiment Videos

Insights

High-risk patients experienced high cardiovascular mortality and morbidity due to inadequate medical treatment. End organ damage and prior vascular events significantly increased risk, necessitating aggressive interventions.

Area of Science:

  • Cardiology
  • Vascular Medicine
  • Public Health

Background:

  • Guidelines prioritize high-risk individuals, but implementation remains suboptimal.
  • Cardiovascular disease poses a significant health burden globally.

Purpose of the Study:

  • To evaluate cardiovascular mortality and morbidity in a high-risk Turkish population.
  • To assess the impact of risk factors and medication usage on outcomes.

Main Methods:

  • A multicenter, observational follow-up study of 5600 patients aged 55+ at high risk for vascular events.
  • Patients were assessed for risk factors and medication use, then followed for 1 year for primary (death, myocardial infarction, stroke) and secondary (revascularization, hospitalization) endpoints.

Main Results:

  • 1-year mortality was higher in patients with end organ damage (5.8% vs 2.7%) and those with previous vascular events (7.8% vs 5.3%).
  • Use of key cardiovascular medications (antiplatelets, statins, beta-blockers, ACE inhibitors) was low and did not improve.
  • Predictors of mortality included end organ damage (OR 1.65) and prior vascular disease (OR 1.49); ACE inhibitor use was protective (OR 0.49).

Conclusions:

  • Cardiovascular mortality and morbidity were unacceptably high in this high-risk Turkish cohort, with inadequate medical treatment.
  • End organ damage and previous vascular events are critical risk factors that require aggressive management.
  • Urgent lifestyle modification and intensified medical therapy are recommended for these high-risk patients.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Imaging Studies for Cardiovascular System I:Echocardiography01:17

Imaging Studies for Cardiovascular System I:Echocardiography

Cardiac imaging studies encompass a wide range of noninvasive and minimally invasive techniques designed to visualize the heart's structure and function in detail. One such technique is echocardiography, which uses high-frequency ultrasound waves to produce detailed images of the heart, known as echocardiograms.
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion, evaluates...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...